Arbor Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.4Mgeneral payments (2019-2025)
$3.4Mresearch payments (2019-2025)
25,898clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Anthony Rostain | Camden, NJ | Psychiatry | $43,945.82 |
| Stelios Mantis | Chicago, IL | Pediatric Endocrinology | $21,385.75 |
| Elizabeth Ofili | Atlanta, GA | Cardiovascular Disease | $16,949.86 |
| Jeffrey Newcorn | New York, NY | Child & Adolescent Psychiatry | $15,059.50 |
| Jack Turban | Palo Alto, CA | Psychiatry | $15,000.00 |
| Nancy Wright | Tallahassee, FL | Pediatric Endocrinology | $13,958.30 |
| John Winkelman | Boston, MA | Sleep Medicine (Psychiatry & Neurology) | $10,128.19 |
| Matthew Feldt | Kansas City, MO | Pediatric Endocrinology | $9,275.78 |
| Karen Klein | San Diego, CA | Pediatric Endocrinology | $7,794.07 |
| Steven Kalkanis | Detroit, MI | Neurological Surgery | $6,397.50 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.